EICHORCondition: Non Muscle Invasive Bladder Cancer · Urologic Cancer · Bladder Cancer · Sponsor: CG Oncology, Inc.
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Urology Centers of Alabama PC | Homewood, Alabama, United States | — |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| Mayo Clinic | Scottsdale, Arizona, United States | — |
| Arizona Institute of Urology PLLC | Tucson, Arizona, United States | — |
| Arkansas Urology PA | Little Rock, Arkansas, United States | — |
| Michael G. Oefelein MD Clinical Trials | Bakersfield, California, United States | — |
| USC/Keck Department of Urology | Los Angeles, California, United States | — |
| Tower Urology | Los Angeles, California, United States | — |
| Sun Kim Urology | Orange, California, United States | — |
| University of California Irvine Medical Center (UCIMC) | Orange, California, United States | — |
| University of California Davis Cancer Center | Sacramento, California, United States | — |
| Stanford University School of Medicine | Stanford, California, United States | — |
+ 83 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06111235